Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Income from Continuing Operations (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Income from Continuing Operations data on record, last reported at 21100000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 78.37% year-over-year to 21100000.0; the TTM value through Dec 2025 reached 68738000.0, up 48.69%, while the annual FY2025 figure was 68738000.0, 47.95% up from the prior year.
  • Income from Continuing Operations reached 21100000.0 in Q4 2025 per ACRS's latest filing, down from 15330000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 4047000.0 in Q4 2023 and bottomed at 97571000.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 23866750.0, with a median of 20584500.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: soared 86.08% in 2023, then crashed 2310.95% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 22893000.0 in 2021, then fell by 27.02% to 29079000.0 in 2022, then skyrocketed by 86.08% to 4047000.0 in 2023, then plummeted by 2310.95% to 97571000.0 in 2024, then skyrocketed by 78.37% to 21100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 21100000.0 in Q4 2025, 15330000.0 in Q3 2025, and 16390000.0 in Q2 2025.